The first patients in a phase 3 study have been dosed with EBI-005 for the treatment of moderate to severe allergic conjunctivitis, Eleven Biotherapeutics announced in a press release. The pivotal trial is designed to evaluate the safety and efficacy o…
Phase 3 study of EBI-005 for treatment of allergic conjunctivitis underway
The first patients in a phase 3 study have been dosed with EBI-005 for the treatment of moderate to severe allergic conjunctivitis, Eleven Biotherapeutics announced in a press release. The pivotal trial is designed to evaluate the safety and efficacy o…
Phase 3 study of EBI-005 for treatment of allergic conjunctivitis underway
The first patients in a phase 3 study have been dosed with EBI-005 for the treatment of moderate to severe allergic conjunctivitis, Eleven Biotherapeutics announced in a press release. The pivotal trial is designed to evaluate the safety and efficacy o…
Phase 3 study of EBI-005 for treatment of allergic conjunctivitis underway
The first patients in a phase 3 study have been dosed with EBI-005 for the treatment of moderate to severe allergic conjunctivitis, Eleven Biotherapeutics announced in a press release. The pivotal trial is designed to evaluate the safety and efficacy o…
Health Canada approves use of iStent inject
Health Canada has approved iStent inject to be used as standalone procedure or in conjunction with cataract surgery to reduce IOP, according to a Glaukos press release.The approval is for reduction of IOP in patients diagnosed with primary open-angle g…
Re-evaluating the Treatment of Acute Optic Neuritis
This article reviews emerging technologies for the assessment of optic nerve structure and function in MS-associated optic neuritis. What new treatments might hold promise? Journal of Neurology, Neurosurgery, and Psychiatry